Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

By P. Hassoun, J. Krishnan. New England Journal of Medicine, 2004

793 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. (2005, methodology): “To further evaluate the relationship of LDH to severity of pulmonary hypertension, we compared the LDH values for 3 groups of patients: (1) no pulmonary hypertension, defined as TRV less than 2.”
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. (2005, methodology): “0 m/s corresponds to moderate to severe pulmonary hypertension.(29) Pulmonary hypertension was prospectively defined as a tricuspid regurgitant jet velocity of at least 2.”
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. (2005, background): “Markers of hemolysis, including anemia, bilirubin, lactate dehydrogenase (LDH), and aspartate aminotransferase (but not liver-specific alanine aminotransferase), were associated with pulmonary hypertension.(22) In addition to limiting nitric oxide bioavailability via hemoglobin-based nitric oxide sc”
Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society (2015, background): “common in adults with SCD and is strongly associated with increased mortality.(601) According to cardiac catheterization”